Clover Biopharmaceuticals has pulled the plug on its partnership with GlaxoSmithKline to develop a COVID-19 vaccine using the UK giant's adjuvant, plumping instead to go into late-stage trials with an adjuvant from Dynavax Technologies Corporation of the US.
China-headquartered Clover had been evaluating its protein-based S-Trimer COVID-19 vaccine in a Phase I trial with two adjuvant, one from GSK and the other from Dynavax. While both performed well and induced high levels of neutralizing antibodies while demonstrating favorable safety and tolerability profiles, Clover is to initiate a global Phase II/III study using Dynavax's CpG 1018 plus alum adjuvant due to its "differentiated, beneficial reactogenicity and safety profile which could make it attractive for a broad population of peoples," the Chengdu-based group said
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?